Table 1 Baseline demographic and disease characteristics of patients with psoriasis
From: Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis
Randomized patients, n | 149 |
Age, years, Mean ± SD | 46.3 ± 12.8 |
Sex | |
Men, n (%) | 114 (76.5) |
White, n (%) | 133 (89.3) |
Psoriasis body surface area involvement, Mean ± SD | 29.5 ± 18.6 |
Psoriasis Area and Severity Index (PASI) score, Mean ± SD | 21.3 ± 9.0 |
Psoriatic arthritis, n (%) | 38 (25.5) |
Body Mass Index (BMI), n (%) | |
N | 148 |
Normal (BMI <25) | 29 (19.6) |
Overweight (BMI ≥25 and <30) | 46 (31.1) |
Obese (BMI ≥30) | 73 (49.3) |
Metabolic Syndrome, n (%)a | 41 (27.5) |
Cigarette smoking, n (%) | |
Current | 50 (33.6) |
Past or current | 97 (65.1) |
Relevant medical history, n (%) | |
ASCVDb | 6 (4.0) |
Diabetes mellitus | 21 (14.1) |
Hypertension | 41 (27.5) |
Hyperlipidemia | 31 (20.8) |
Family history of early ASCVD | 15 (10.1) |
High-density lipoprotein (HDL), n | 141 |
Mean ± SD | 47.9 ± 12.9 |
HDL <40 mg/dL, n (%) | 43 (30.5) |
Low-density lipoprotein, n | 137 |
Mean ± SD | 113.1 ± 35.7 |
Triglycerides, n | 141 |
Median (IQ range) | 134.0 (99.0, 182.0) |
Total Cholesterol, n | 141 |
Mean ± SD | 191.8 ± 40.0 |
Total Cholesterol/HDL, Mean ± SD | 4.3 ± 1.4 |